References
- BlinderKJBlumenkranzMSBresslerNMVerteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial – VIP report no. 3Ophthalmology200311066767312689884
- SoubraneGChoroidal neovascularisation in pathologic myopia: recent developments in diagnosis and treatmentSurv Opthalmol200853121138
- SecretanMKuhnDSoubraneGCoscasGLong term visual outcome of choroidal neovascularisation in pathologic myopia: natural history and laser treatmentEur J Ophthalmol199773073169457451
- HamelinNGlacet-BernardABrindeauCMimounGCoscasGSoubraneGSurgical treatment of subfoveal neovascularisation in myopia: macular translocation vs surgical removalAm J Ophthalmol200213353053611931787
- Ruiz-MorenoJMde la VegaCSurgical removal of subfoveal choroidal neovascularisation in highly myopic patientsBr J Ophthalmol2001851041104311520751
- MateoCMorenoJRosalesGTwo-year results of macular translocation with sclera infolding in myopic choroidal neovascularisationSemin Ophthalmol200419294215590532
- MonteroJARuiz-MorenoJMCombined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot studyBr J Ophthalmol20079113113317244656
- ChanWMLaiTYYLiuDTLLamDSCIntravitreal bevacizumab (Avastin) for myopia choroidal neovascularisation: six-month results of a prospective pilot studyOphthalmology20071142190219617599414
- NguyenQDShahSTatlipinarSDoDVAndenEVCampochiaroPABevacizumab suppresses choroidal neovascularisation caused by pathological myopiaBr J Ophthalmol2005891368137016170134
- YamamotoIRogersAHReichelEYatesPADukerJSIntravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopiaBr J Ophthalmol20079115716016870653
- KonstantinidisLMantelIPournarasJACZografosLAmbresinAIntravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularisationGraefes Arch Clin Exp Ophthalmol200924731131819043731
- IkunoYSayanagiKSogaKIntravitreal bevacizumab for choroidal neovascularisation attributable to pathological myopia: one year resultsAm J Ophthalmol20091479410018774550
- VoykovBGeliskenFInhoffenWVoelkerMBartz-SchmidtKUZiemssenFBevacizumab for choroidal neovascularisation secondary to pathologic myopia: is there a decline of the treatment efficacy after 2 years?Graefes Arch Clin Exp Ophthalmol201024854355020111971
- RosenfeldPJBrownDMHeierJSRanibizumab for neovascular age-related macular degenerationN Engl J Med20063551419143117021318
- Calvo-GonzalezCReche-FrutosJDonateJFernandez-PerezCGarcia-FeijooJIntravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatmentAm J Ophthalmol201115152955421236413
- SilvaRMRuiz-MorenoJMRosaPIntravitreal ranibizumab for myopic choroidal neovascularization: 12-month resultsRetina20103040741220094007
- MonesJMAmselemLSerranoAGarciaMHijanoMIntravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month resultsEye2009231275128019478826
- KumaranNSimDATufailALong-term remission of myopic choroidal neovascular membrane after treatment with ranibizumab: A case reportJ Med Case Reports200938419946560
- LaiTYChanWMLiuDTLamDSIntravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopiaRetina20092975075619357555
- TorronCEgeaCFerrerERuizOHonrubiaFMRanibizumab as treatment for myopic choroidal neovascularizationArch Soc Esp Oftalmol200984507514 Spanish.19902395
- SilvaRMRuiz-MorenoJMNascimentoJShort-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularizationRetina2008281117112318788102